Aerovate Therapeutics (NASDAQ:AVTE) Issues Earnings Results

Aerovate Therapeutics (NASDAQ:AVTE) posted its earnings results on Thursday. The company reported ($0.19) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.19), Zacks reports.

Aerovate Therapeutics Stock Performance

Aerovate Therapeutics stock traded up $0.01 during trading on Friday, reaching $2.54. The company had a trading volume of 19,129 shares, compared to its average volume of 575,236. The firm has a market capitalization of $73.20 million, a PE ratio of -0.85 and a beta of 1.01. The firm’s 50-day simple moving average is $2.50 and its 200 day simple moving average is $2.43. Aerovate Therapeutics has a 1-year low of $1.25 and a 1-year high of $32.42.

About Aerovate Therapeutics

Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.